特一藥業(002728.SZ):上半年淨利潤預降97.90%-98.49%
格隆匯7月8日丨特一藥業(002728.SZ)公佈2024年半年度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利230萬元—320萬元,比上年同期下降98.49%—97.90%;扣除非經常性損益後的淨利潤盈利180萬元—270萬元,比上年同期下降98.80%—98.21%;基本每股收益盈利0.005元/股—0.006元/股。
報吿期,公司進行營銷組織變革,對原有的組織架構和營銷渠道進行優化和調整。通過營銷組織變革,在藥店的銷售方面,公司逐步由經銷商模式調整為自營+經銷商的混合模式。由於營銷組織變革和營銷模式的調整,也涉及到銷售渠道的銜接和對部分藥店銷售業務的交接。在這個過程中,為了保證變革的順利推進,公司減少了核心產品止咳寶片的發貨,導致毛利較高的止咳寶片銷售收入同比降幅較大。同時,為了進一步提高特一品牌的市場知名度和美譽度,公司在減少止咳寶片產品發貨的同時,未相應減少品牌宣傳的費用,當期銷售費用佔比較高。這些導致了公司本報吿期業績下降幅度較大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.